| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
Divisions of 1 Epigenetics, 2 Molecular Toxicology, and 3 Molecular Biophysics, Deutsches Krebsforschungszentrum, Heidelberg, Germany; 4 Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland
Requests for reprints: Frank Lyko, Division of Epigenetics, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany. Phone: 49-6221-42-3800; Fax: 49-6221-42-3802; E-mail: f.lyko{at}dkfz.de.
DNA methylation regulates gene expression in normal and malignant cells. The possibility to reactivate epigenetically silenced genes has generated considerable interest in the development of DNA methyltransferase inhibitors. Here, we provide a detailed characterization of RG108, a novel small molecule that effectively blocked DNA methyltransferases in vitro and did not cause covalent enzyme trapping in human cell lines. Incubation of cells with low micromolar concentrations of the compound resulted in significant demethylation of genomic DNA without any detectable toxicity. Intriguingly, RG108 caused demethylation and reactivation of tumor suppressor genes, but it did not affect the methylation of centromeric satellite sequences. These results establish RG108 as a DNA methyltransferase inhibitor with fundamentally novel characteristics that will be particularly useful for the experimental modulation of epigenetic gene regulation.
This article has been cited by other articles:
![]() |
A. Dombrovsky, L. Arthaud, T. N. Ledger, S. Tares, and A. Robichon Profiling the repertoire of phenotypes influenced by environmental cues that occur during asexual reproduction Genome Res., November 1, 2009; 19(11): 2052 - 2063. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Evison, R. A. Bilardi, F. C. K. Chiu, G. Pezzoni, D. R. Phillips, and S. M. Cutts CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity Nucleic Acids Res., October 1, 2009; 37(19): 6355 - 6370. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ellis, P. W. Atadja, and R. W. Johnstone Epigenetics in cancer: Targeting chromatin modifications Mol. Cancer Ther., June 1, 2009; 8(6): 1409 - 1420. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Datta, K. Ghoshal, W. A. Denny, S. A. Gamage, D. G. Brooke, P. Phiasivongsa, S. Redkar, and S. T. Jacob A New Class of Quinoline-Based DNA Hypomethylating Agents Reactivates Tumor Suppressor Genes by Blocking DNA Methyltransferase 1 Activity and Inducing Its Degradation Cancer Res., May 15, 2009; 69(10): 4277 - 4285. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rius, C. Stresemann, D. Keller, M. Brom, E. Schirrmacher, D. Keppler, and F. Lyko Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation Mol. Cancer Ther., January 1, 2009; 8(1): 225 - 231. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Link, M. R. Baer, S. R. James, D. A. Jones, and A. R. Karpf p53-Inducible Ribonucleotide Reductase (p53R2/RRM2B) Is a DNA Hypomethylation-Independent Decitabine Gene Target That Correlates with Clinical Response in Myelodysplastic Syndrome/Acute Myelogenous Leukemia Cancer Res., November 15, 2008; 68(22): 9358 - 9366. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. D. Lubin, T. L. Roth, and J. D. Sweatt Epigenetic Regulation of bdnf Gene Transcription in the Consolidation of Fear Memory J. Neurosci., October 15, 2008; 28(42): 10576 - 10586. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Stresemann, I. Bokelmann, U. Mahlknecht, and F. Lyko Azacytidine causes complex DNA methylation responses in myeloid leukemia Mol. Cancer Ther., September 1, 2008; 7(9): 2998 - 3005. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Brueckner, C. Stresemann, R. Kuner, C. Mund, T. Musch, M. Meister, H. Sultmann, and F. Lyko The Human let-7a-3 Locus Contains an Epigenetically Regulated MicroRNA Gene with Oncogenic Function Cancer Res., February 15, 2007; 67(4): 1419 - 1423. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Stresemann, B. Brueckner, T. Musch, H. Stopper, and F. Lyko Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res., March 1, 2006; 66(5): 2794 - 2800. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rouhi, L. Gagnier, F. Takei, and D. L. Mager Evidence for epigenetic maintenance of Ly49A monoallelic gene expression. J. Immunol., March 1, 2006; 176(5): 2991 - 2999. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Lyko and R. Brown DNA Methyltransferase Inhibitors and the Development of Epigenetic Cancer Therapies J Natl Cancer Inst, October 19, 2005; 97(20): 1498 - 1506. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |